Explore a multi-device strategy for tackling complex calcified coronary lesions in this session. It includes case studies on left main trifurcation stenting, resistant calcified nodules treated with orbital atherectomy, severe restenosis, and critical calcifications in challenging anatomies, showcasing advanced techniques for plaque modification and lesion management.

This session highlights innovative transcatheter aortic valve implantation (TAVI) approaches for treating aortic regurgitation, focusing on off-label uses and complex cases. It features high-risk patient interventions, including nonagenarian patients, and strategies to manage severe non-calcific native valve regurgitation with balloon-expandable valves.

This session explores alternative access strategies for Transcatheter Aortic Valve Implantation (TAVI) when the transfemoral route is not feasible. It covers complex scenarios including transcaval TAVI complications, transaxillary approaches, management of extra-large annuli with peripheral artery disease, and innovative transcarotid valve-in-valve procedures.

Delve into advanced imaging and physiology-guided drug-coated balloon (DCB) strategies for complex coronary lesions. This session presents integrated approaches combining morphology and physiology, OCT guidance, and real-world cases highlighting DCB use in multivessel disease and calcified lesions.

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.